BPT-143

BPT-143 is a fully synthetic, PEGylated interleukin-2 (IL-2) variant developed using chemical protein synthesis technology by Bright Peak Therapeutics. It is an "alpha-dead, beta-gamma preserved" IL-2, meaning it has been engineered to eliminate binding to the IL‑2 receptor alpha chain (CD25), while retaining activity at the beta and gamma chains (CD122/CD132). This design aims to selectively stimulate effector immune cells such as CD8+ T cells and NK cells with minimal activation of regulatory T cells (Tregs), thereby enhancing anti-tumor immunity while reducing toxicity associated with traditional high-dose IL‑2 therapies. In preclinical models, BPT‑143 demonstrated robust single-agent anti-tumor activity, induced complete tumor regression in vivo, and promoted immunologic memory. The molecule is PEGylated for improved pharmacokinetics and half-life extension. It is currently in preclinical development for cancer indications[1][4][5][7].

Other names

next-generation IL-2 conjugate